0001193125-23-169187.txt : 20230620 0001193125-23-169187.hdr.sgml : 20230620 20230616185429 ACCESSION NUMBER: 0001193125-23-169187 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230615 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230620 DATE AS OF CHANGE: 20230616 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MADRIGAL PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001157601 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33277 FILM NUMBER: 231022804 BUSINESS ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 BUSINESS PHONE: 404-380-9263 MAIL ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 FORMER COMPANY: FORMER CONFORMED NAME: SYNTA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20010815 8-K 1 d521638d8k.htm 8-K 8-K
false 0001157601 --12-31 0001157601 2023-06-15 2023-06-15

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 15, 2023

 

 

MADRIGAL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-33277   04-3508648

(State or another jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

Four Tower Bridge    
200 Barr Harbor Drive, Suite 200    
West Conshohocken, Pennsylvania     19428
(Address of principal executive offices)     (Zip Code)

(267) 824-2827

Registrant’s telephone number, including area code

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 Par Value Per Share   MDGL   The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

On June 16, 2023, Madrigal Pharmaceuticals, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Restated Certificate of Incorporation, as amended, to provide exculpation from liability for certain officers of the Company from certain claims of breach of the fiduciary duty of care, as described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on May 1, 2023 and as approved at the Company’s 2023 Annual Meeting of Stockholders (the “Annual Meeting”). The Certificate of Amendment became effective on upon filing with the Secretary of State.

A copy of the Certificate of Amendment is filed herewith as Exhibit 3.1 and incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

(a) 2023 Annual Meeting of Stockholders

The Company held the Annual Meeting on a virtual basis via internet at 9:00 a.m., Eastern time, on Thursday, June 15, 2023. As of April 27, 2023, the record date for the Annual Meeting, the Company had 18,289,173 shares of its common stock outstanding and entitled to vote, of which 16,146,504 shares of the Company’s common stock were present in person or represented by proxy and entitled to vote, constituting a quorum, at the Annual Meeting.

(b) Annual Meeting Voting Results

The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Annual Meeting. These matters are described in more detail in the Proxy Statement filed with the SEC on May 1, 2023.

Proposal No. 1: The Company’s stockholders elected each of the three Class I nominees named below to serve on the Company’s Board of Directors for a three-year term expiring at the Company’s 2026 annual meeting of stockholders and until their respective successors are duly elected and qualified.

 

Class I Nominee

    Votes For    Votes Withheld    Broker Non-votes

Paul A. Friedman, M.D.

    14,114,309    750,859    1,281,336

Kenneth M. Bate

    13,914,837    950,331    1,281,336

James M. Daly

    8,913,220    5,951,948    1,281,336

Proposal No. 2: The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.

 

Votes For

  

Votes Against

  

Votes Abstaining

  

Broker Non-Votes

16,111,585   12,542   22,377   —

Proposal No. 3: The Company’s stockholders approved, on an advisory basis (with the affirmative vote of 93.56% of the votes cast FOR), the compensation of the Company’s named executive officers as described in the Proxy Statement.

 

Votes For

  

Votes Against

  

Votes Abstaining

  

Broker Non-Votes

13,908,736   940,302   16,130   1,281,336

Proposal No. 4: The Company’s stockholders approved the Amendment to Company’s Restated Certificate of Incorporation, as described in the Proxy Statement.

 

Votes For

  

Votes Against

  

Votes Abstaining

  

Broker Non-Votes

13,898,961   958,185   8,022   1,281,336

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No.		   

Description

3.1    Certificate of Amendment to Restated Certificate of Incorporation of Madrigal Pharmaceuticals, Inc., as filed on June 16, 2023 with the Secretary of State of the State of Delaware
104    Cover Page Interactive Data File (embedded within the Inline XBRL file)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    MADRIGAL PHARMACEUTICALS, INC.
Date: June 16, 2023      

/s/ Brian J. Lynch

      Brian J. Lynch
      Senior Vice President and General Counsel

 

 

3

EX-3.1 2 d521638dex31.htm EX-3.1 EX-3.1

EXHIBIT 3.1

CERTIFICATE OF AMENDMENT OF

RESTATED CERTIFICATE OF INCORPORATION

MADRIGAL PHARMACEUTICALS, INC.

(Pursuant to Section 242 of the

General Corporation Law of the State of Delaware)

Madrigal Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware, does hereby certify:

1.    This Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the Restated Certificate of Incorporation of the Corporation (the “Restated Certificate of Incorporation”) filed with the Secretary of State of the State of Delaware on February 9, 2007, as amended.

2.    The Restated Certificate of Incorporation is hereby amended by adding Article TWELFTH to read in its entirety as follows:

“TWELFTH: To the fullest extent that the Delaware General Corporation Law, as the same exists or may hereafter be amended, permits the limitation or elimination of the liability of officers, no officer of the Corporation shall be personally liable to the Corporation or its stockholders for any monetary damages for breach of fiduciary duty as an officer. No amendment to, or modification or repeal of this Article TWELFTH, nor the adoption of any provision of this Restated Certificate of Incorporation inconsistent with this Article TWELFTH, shall adversely affect any right or protection of an officer existing hereunder with respect to any act or omission occurring prior to such amendment, modification, repeal or adoption of an inconsistent provision. If the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability of officers, then the liability of an officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended.”

3.    This Certificate of Amendment was duly adopted by the Board of Directors of the Corporation and by the stockholders of the Corporation in accordance with Section 242 of the General Corporation Law of the State of Delaware.

EXECUTED, this 15th day of June 2023

 

Madrigal Pharmaceuticals, Inc.
By:  

/s/ Brian J. Lynch

Brian J. Lynch
Senior Vice President and General Counsel
 EX-101.SCH 3 mdgl-20230615.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 mdgl-20230615_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 mdgl-20230615_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
Jun. 15, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001157601
Current Fiscal Year End Date --12-31
Document Type 8-K
Document Period End Date Jun. 15, 2023
Entity Registrant Name MADRIGAL PHARMACEUTICALS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-33277
Entity Tax Identification Number 04-3508648
Entity Address, Address Line One Four Tower Bridge
Entity Address, Address Line Two 200 Barr Harbor Drive
Entity Address, Address Line Three Suite 200
Entity Address, City or Town West Conshohocken
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19428
City Area Code (267)
Local Phone Number 824-2827
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 Par Value Per Share
Trading Symbol MDGL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 d521638d8k_htm.xml IDEA: XBRL DOCUMENT 0001157601 2023-06-15 2023-06-15 false 0001157601 --12-31 8-K 2023-06-15 MADRIGAL PHARMACEUTICALS, INC. DE 001-33277 04-3508648 Four Tower Bridge 200 Barr Harbor Drive Suite 200 West Conshohocken PA 19428 (267) 824-2827 false false false false Common Stock, $0.0001 Par Value Per Share MDGL NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 25 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d521638d8k.htm d521638dex31.htm mdgl-20230615.xsd mdgl-20230615_lab.xml mdgl-20230615_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d521638d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 25 }, "contextCount": 1, "dts": { "inline": { "local": [ "d521638d8k.htm" ] }, "labelLink": { "local": [ "mdgl-20230615_lab.xml" ] }, "presentationLink": { "local": [ "mdgl-20230615_pre.xml" ] }, "schema": { "local": [ "mdgl-20230615.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mdgl", "nsuri": "http://www.madrigalpharma.com/20230615", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d521638d8k.htm", "contextRef": "duration_2023-06-15_to_2023-06-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d521638d8k.htm", "contextRef": "duration_2023-06-15_to_2023-06-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.madrigalpharma.com//20230615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001193125-23-169187-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-169187-xbrl.zip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end